Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bivalent COVID-19 mRNA vaccine
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Bivalent COVID-19 mRNA Vaccine refers to a category of next-generation vaccines developed by Pfizer-BioNTech and Moderna to provide broader protection against SARS-CoV-2. These vaccines utilize lipid nanoparticle-encapsulated messenger RNA (mRNA) encoding the spike protein of two different strains: the original Wuhan-Hu-1 strain and an Omicron subvariant (initially BA.1, and subsequently BA.4/BA.5). By presenting two versions of the spike protein to the immune system, the vaccine elicits a broader neutralizing antibody response compared to the original monovalent vaccines. They were authorized by the FDA under Emergency Use Authorization (EUA) in late 2022 as booster doses to address the waning immunity and the emergence of immune-evasive variants.
- Brand names
- ComirnatySpikevax
- Other names
- bivalent COVID-19 mRNA vaccineOmicron-adapted COVID-19 vaccinebivalent booster
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on bivalent COVID-19 mRNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bivalent COVID-19 mRNA vaccine.